Thin-layer chromatographic determination of imipramine and desipramine in human plasma and urine at single-dose levels.
Thin-layer chromatographic methods were up-dated for pharmacokinetic studies of imipramine in plasma and urine. The free parent compound and its free desmethyl metabolite desipramine are determined in plasma. Conjugates of both compounds in urine are cleaved on treatment with glucuronidase/arylsulfatase. Following chromatography, intense yellow derivatives are obtained overnight on standing or by exposure to nitrous gases. Detection is performed in the visible range at 405 nm (plasma) or 460 nm (urine). The methods are selective, accurate and sensitive, with detection limits for plasma of 2 ng/ml imipramine--HCl and 2 ng/ml desipramine--HCl, and 0.06 micrograms/ml total imipramine--HCl and 0.126 micrograms/ml total desipramine--HCl for urine. Pharmacokinetic data from plasma and urine results following single oral doses of 50 mg imipramine--HCl to eight volunteers were computed using one-compartment open models.
D000328:Adult; D002855:Chromatography, Thin Layer / Q000379:methods; D003891:Desipramine / Q000032:analysis* / Q000097:blood / Q000652:urine; D006207:Half-Life; D006801:Humans; D007099:Imipramine / Q000032:analysis* / Q000097:blood / Q000652:urine; D007700:Kinetics; D008297:Male; D008954:Models, Biological
D007099:Imipramine; D003891:Desipramine